title: Intravitreal bevacizumab treatment of macular edema in central retinal vein occlusion: one-year results.
abstract: OBJECTIVE
  To report on the anatomic and visual acuity response after intravitreal bevacizumab injection in patients with macular edema due to non-ischemic central retinal vein occlusion (CRVO).
  
  
  METHODS
  In a retrospective study, 21 consecutive patients (21 eyes) with non-ischemic CRVO underwent, on average, 3.7 intravitreal bevacizumab injections (1.25 mg). Ophthalmic examination included best corrected visual acuity (BCVA) and central retinal thickness (CRT) at baseline and follow-up visits. Fluorescein angiography was performed at baseline and at follow-up visits if needed. Primary outcomes were change of BCVA and CRT.
  
  
  RESULTS
  The follow-up period for all of the included patients was 12 months. The mean BCVA was unchanged at the 12-month examination (baseline: 20/160; 12 months: 20/160) (P = 0.771). The mean CRT decreased from 780 microm (standard deviation [SD] +/- 324 microm) at the baseline to a mean of 462 microm (SD +/- 248 microm) at 12 months (P < 0.05).
  
  
  CONCLUSIONS
  Intravitreal bevacizumab resulted in a significant decrease in CRT without significant improvement of visual acuity in patients with non-ischemic CRVO after a follow-up of 12 months.
authors.affiliation: Eye Hospital, University Clinic of Schleswig-Holstein, Campus Lübeck, Lübeck, Germany. julia.beutel@med.uni-tuebingen.de
authors.forename: Julia
authors.initials: J
authors.lastname: Beutel
authors.forename: Focke
authors.initials: F
authors.lastname: Ziemssen
authors.forename: Matthias
authors.initials: M
authors.lastname: Lüke
authors.forename: Michael
authors.initials: M
authors.lastname: Partsch
authors.forename: Karl-Ulrich
authors.initials: KU
authors.lastname: Bartz-Schmidt
authors.forename: Faik
authors.initials: F
authors.lastname: Gelisken
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D056965:Injections, Intraocular; D008269:Macular Edema / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D008297:Male; D008875:Middle Aged; D012160:Retina / Q000187:drug effects / Q000473:pathology; D012170:Retinal Vein Occlusion / Q000150:complications* / Q000473:pathology; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome; D014792:Visual Acuity
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab